As the world’s first non-leaching antimicrobial glove (AMG), GloveOn Protect is the next game-changing innovation for reducing healthcare associated infections (HAIs).
Our AMG technology has been designed to reduce bacterial loads that could be transferred to patients from their environment by up to 99.999%, and can be used in settings such as hospitals, emergency services and aged care facilities.
Health and Financial Impacts of HAIs
In Australia, the average incidence of HAIs from 2010 to 2016 came to 165,000 annually (Mitchell et al. 2017). It is of tremendous importance to address the problem of antimicrobial resistance and help prevent the cost of HAIs. If no action is taken to halt the spread of multi-drug resistant bacteria, by the year 2050 we will see 300 million untimely deaths at a cost of $100 trillion to the world economy (Kashef et al., 2017).
A Novel Approach
GloveOn Protect adds to the multi-modal approach for combating HAIs and preventing contamination and transmission of pathogens from healthcare workers contact with patients and their environment. Our AMG technology has been created to work alongside existing infection control methods of best practice, including hand hygiene, isolation
and staffing, surface disinfection, and antibiotics.
What makes GloveOn Protect so groundbreaking?
Non-leaching to provide safety to both patients and workers
Effective against a wide range of bacteria including staphylococci and enterococci
A non-specific kill mechanism to reduce the likelihood of bacterial resistance
Figure 2. Photodynamic Reaction of AMG Technology
How AMG Technology Works
Photosensitisers, a non-toxic dye, is the catalyst behind our AMG technology and is bound to the outer surface of the glove. When exposed to light, the photosensitisers channel energy to any ground state molecular oxygen (3O2) it makes contact with, resulting in the creation of the reactive oxygen species (ROS) known as singlet oxygen (1O2) (Kashef et al., 2017).
This ROS attacks the microbe’s proteins and lipids, resulting in
the destruction of harmful bacteria which get transferred to the glove from the patient’s environment.
The photodynamic reaction of this promising approach to microbial infections is captured in Figure 2.
According to the ASTM D7907 Standard Test Methods for Determination of Bactericidal Efficacy on the Surface of Medical Examination Gloves, antimicrobial gloves are effective in killing antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin resistant enterococci (VRE).
MRSA and VRE are known high profile microbes responsible for HAIs in healthcare facilities across the globe. Studies have shown that patients residing in rooms previously occupied by MRSA and VRE infected patients had a higher risk of contracting these pathogens (Russotto et al., 2015).
The antimicrobial properties of GloveOn Protect have been proven to kill up to 99.999% of microbes, such as Staphylococcus aureus, in a short time of five minutes.
Help Educate Your Team Today with Our Free Brochure
To download information about HAIs, the role of medical gloves, AMG technology, and frequently asked questions about the latest innovation in infection control, simply fill in the form here and follow the prompts.
1. ‘Kashef, N, Hamblin, MR 2017, ‘Can microbial cells develop resistance to oxidative stress in antimicrobial photodynamic inactivation?’, Drug Resistance Updates, vol. 31, pp. 31-42
2. Mitchell, BG, Shaban, RZ, MacBeth, D, Wood, CJ, Russo, PL 2017, ‘The burden of healthcare-associated infection in Australian hospitals: A systematic review of the literature’, Infection, Disease & Health, vol. 22, pp. 117-128.
3. Russotto, V, Cortegiani, A, Raineri, SM, Giarratano, A 2015, ‘Bacterial contamination of inanimate surfaces and equipment in the intensive care unit’, Journal of Intensive Care, vol. 3, accessed 9 August 2017, <https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-015-0120-5>
4. Wainwright, M, Maisch, T, Nonell, S, Plaetzer, K, Almeida, A, Tegos, GP, Hamblin, MR 2017, ‘Photoantimicrobials–are we afraid of the light?’, The Lancet Infectious Diseases,vol. 17, pp. 49-55.